Buscar
Mostrando ítems 1-10 de 21
Envisioning a hepatitis delta cure with new antivirals
(Future Medicine Ltd., 2021)
Envisioning a hepatitis delta cure with new antivirals
Ultra-long-acting antivirals as chemical vaccines to prevent viral diseases
(Future Microbiology, 2022-07)
For two centuries, vaccines have been successful in the fight against viruses, triggering immune protection. Indeed, the elimination of smallpox, the only infectious disease eradicated to date, was made possible through ...
A greater virulent HIV-1 subtype B variant has circulated in The Netherlands since the 1990’s
(AIDS Reviews, 2022)
Despite being COVID-19 the global focus of attention nowadays, other pandemics caused by RNA viruses are ongoing. This is the case for AIDS. Roughly, 38 million people are, at present, living with HIV-1 infection worldwide ...
Oral antivirals for the prevention and treatment of SARS-CoV-2 infection
(AIDS Reviews, 2022)
Vaccines and antivirals are the classical weapons deployed to contain, prevent, and treat life-threatening
viral illnesses. Specifically, for SARS-CoV-2 infection, vaccines protect against severe COVID-19 disease
manifestations ...
The five HIV cures
(Aids Reviews, 2022)
[Resumen no disponible]
Liver cancer and hepatic decompensation events in patients hospitalized with viral hepatitis in Spain
(Hepatology International, 2022)
Background: Chronic viral hepatitis B, C, and D are the main causes of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented more than 2 decades ago in most EU countries. Furthermore, ...
Late presentation of human T-lymphotropic virus type 1 infection in Spain reflects suboptimal testing strategies: on behalf of the Human T-lymphotropic Virus (HTLV) Spanish Network
(International Journal of Infectious Diseases, 2022)
Objectives: Although only 10% of persons infected with human T-lymphotropic virus type 1 (HTLV-1) may develop virus-associated illnesses over their lifetime, missing the earlier diagnosis of asymptomatic carriers frequently ...
Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy
(Drug Design, Development and Therapy, 2023)
It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. The search for molecules interfering with the binding of NTCP and HBV/HDV led to design bulevirtide ...
Is SARS-CoV-2 the only cause of long-COVID?
(AIDS Reviews, 2022)
Around 10% of adults infected with SARS-CoV-2 that survive a first episode of COVID-19 appear to experience long-term clinical manifestations. The signs and symptoms of this post-acute COVID-19 syndrome (PACS) include ...
Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain
(Alimentary Pharmacology and Therapeutics, 2023)
Background: Chronic hepatitis B virus (HBV) infection is a major cause of decompensated cirrhosis and liver cancer worldwide. Newborn HBV vaccination was implemented in Spain two decades ago, and potent oral antivirals ...